Should minimal residual disease negativity be the end point of myeloma therapy?

Kenneth C Anderson, Kenneth C Anderson

Abstract

Publisher's Note: This article has a companion Counterpoint by Sonneveld. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

Figure 1.
Figure 1.
Impact of MRD on patient outcome in patients who have achieved conventional CR. Impact of MRD on PFS was evaluated in 14 studies (1273 patients) and on OS in 12 studies (1100 patients) overall, including the impact of MRD on PFS in 5 studies (574 patients) (A) and OS in 6 studies (616 patients) (B) in the setting of conventional CR. MRD negativity was associated with improved PFS and OS, both overall (P < .001) and in patients who were in CR (P < .001). Modified from Munshi et al with permission.

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
    1. Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445-452.
    1. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126(3):300-310.
    1. Anderson KC, Alsina M, Atanackovic D, et al. . NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016;14(4):389-400.
    1. Dimopoulos M, Spencer A, Attal M, et al. ; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-2132.
    1. McCarthy PL, Owzar K, Hofmeister CC, et al. . Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
    1. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. ; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917.
    1. San Miguel J, Weisel K, Moreau P, et al. . Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
    1. Richardson PG, Siegel DS, Vij R, et al. . Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826-1832.
    1. Richardson PG, Barlogie B, Berenson J, et al. . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-2617.
    1. Richardson PG, Sonneveld P, Schuster MW, et al. ; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498.
    1. San Miguel JF, Schlag R, Khuageva NK, et al. . Bortezomib plus melphalan-prednisone versus melphalan-prednisone in untreated multiple myeloma patients ineligible for stem cell transplantation. N Engl J Med. 2008;359:906-917.
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. ; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
    1. Moreau P, Masszi T, Grzasko N, et al. ; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621-1634.
    1. Lonial S, Dimopoulos M, Palumbo A, et al. ; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
    1. Lokhorst HM, Plesner T, Laubach JP, et al. . Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
    1. Lonial S, Weiss BM, Usmani SZ, et al. . Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
    1. Palumbo A, Chanan-Khan A, Weisel K, et al. ; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766.
    1. Dimopoulos MA, Oriol A, Nahi H, et al. ; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319-1331.
    1. San-Miguel JF, Hungria VT, Yoon SS, et al. . Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
    1. Richardson PG, Weller E, Lonial S, et al. . Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
    1. Kumar SK, Berdeja JG, Niesvizky R, et al. . Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13):1503-1512.
    1. Richardson PG, Xie W, Jagannath S, et al. . A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123(10):1461-1469.
    1. Kumar SK, Dispenzieri A, Lacy MQ, et al. . Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
    1. Palumbo A, Avet-Loiseau H, Oliva S, et al. . Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
    1. Sonneveld P, Avet-Loiseau H, Lonial S, et al. . Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
    1. Kumar S, Paiva B, Anderson KC, et al. . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
    1. Cavo M, Terragna C, Martinelli G, et al. . Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355-357.
    1. Corradini P, Cavo M, Lokhorst H, et al. ; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927-1929.
    1. Galimberti S, Benedetti E, Morabito F, et al. . Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005;29(8):961-966.
    1. Avet-Loiseau H, Corre J, Lauwers-Cances V, et al. . Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial. Blood. 2015;126:191 [abstr]
    1. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059-3068.
    1. Rawstron AC, Gregory WM, de Tute RM, et al. . Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932-1935.
    1. Rawstron AC, Child JA, de Tute RM, et al. . Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
    1. Vij R, Mazumder A, Klinger M, et al. . Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14(2):131-139.e1.
    1. Hocking J, Mithraprabhu S, Kalff A, Spencer A. Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol Med. 2016;13(2):215-225.
    1. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. . Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis [published online ahead of print 15 September 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.3160.
    1. Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis [published online ahead of print 5 September 2016]. Bone Marrow Transplant. doi:10.1038/bmt.2016.222.
    1. Gormley NJ, Farrell AT, Pazdur R. Minimal residual disease as a potential surrogate end point-lingering questions [published online ahead of print 15 September 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.3112.
    1. Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011; 2011:9204058.
    1. Tai YT, Anderson KC. A new era of immune therapy in multiple myeloma. Blood. 2016;128(3):318-319.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren